Become a mentor on Beacon’s Patient Group Mentoring Programme and make a real difference to the rare disease community!
Mentees need support across a wide range of areas, from charity management and fundraising to communications, life sciences and more.
You don’t need a background in rare diseases to have something valuable to offer.
As a mentor, you will:
• Be paired with a rare disease patient group leader for a 12-month partnership
• Grow your leadership skills and aid your professional development
• Give back to organisations making a real difference for people living with rare…
Enedra Therapeutics (Enedra), a pioneering biotechnology company focused on developing novel treatments for genetically heterogeneous cancers, today announced the appointment of Adrian Ibrahim, PhD, MBA, as its new Chief Executive Officer. Dr Ibrahim will also join the Company’s Board of Directors. His appointment comes as Enedra prepares to initiate its seed phase fundraising round.
Dr Ibrahim brings over 30 years of experience in the life sciences spanning academia and biotech with a proven track record as a company founder and executive leader. A strategic leader with deep expertise in…
[Letchworth Garden City, December 2025] – DLRC Group has today announced its certification as a B Corporation (or B Corp), joining a growing movement of companies that are reinventing business for the benefit of all people and our shared planet. Verified by B Lab, the not-for-profit behind the B Corp movement, the achievement demonstrates that DLRC Group meets high standards of social and environmental performance, transparency, and accountability alongside a commitment to goals beyond shareholder value.
The news comes as the ongoing climate crisis and widening social inequality continue…
IRCA Group, a global leader in high-quality food ingredients, has signed a lease at Pioneer Group’s new food and beverage incubator, Gastronomica at Colworth Science Park in Bedfordshire.
IRCA has taken 405 sq ft of space in the facility, providing the company with a strong foothold in the UK market. A specialist in chocolate, creams, fillings, fruits, pistachios and decorations, IRCA currently operates 20 production facilities across Europe, the US, and Vietnam, serving customers in more than 100 countries.
Launched earlier this year, Gastronomica provides flexible workspaces, shared labs…
Experienced biotech Chair and executive will guide corporate growth and development
Cambridge, UK, 2 December 2025: TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced the appointment of Alison Lawton as Chair of its Board of Directors. Alison brings substantial expertise in operations, drug development, and strategic leadership, together with extensive boardroom experience, to guide and support TRIMTECH’s accelerated portfolio advancement and its next…
Creative Biolabs introduces CAR-T therapy research solutions and webinars to help scientists drive innovation in CAR-T development.Creative Biolabs, the world's leading biotechnological solutions provider, today announces its new comprehensive portfolio of solutions to accelerate chimeric antigen receptor T-cell (CAR-T) research. Through its industry-leading platforms, expert scientist guidance and educational webinars, Creative Biolabs is dedicated to helping scientists and research organizations solve technical challenges and drive innovation in CAR-T development. CAR-T…
Read Marks & Clerks AI Report 2025 here.
Continued growth and ongoing mainstream adoption: AI patent publications at the EPO hit an all-time high in 2024, demonstrating the sustained, record-level investment and output in European AI development.
A tale of two innovation races: While the US and South Korea dominate per capita AI patent filings at the EPO - leaving Japan and Europe behind in a widening innovation gap - Japan has surged ahead in quantum AI, overtaking even the US in per capita QAI publications.
Allowance rate discrepancy: The allowance rate for Quantum AI applications at…
Stevenage, UK, 1 December 2025 - NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is pleased to announce expansion of its team with the appointment of Paul Thompson PhD as Chief Development Officer (CDO).
In his role at NRG, Paul will be project lead for NRG5051 which is on track to commence first-in-human studies in early 2026. NRG5051 is an oral, CNS-penetrant small molecule inhibitor of the mitochondrial permeability transition pore (mPTP) acting via a novel mechanism of action (MoA). Inhibition of the mPTP…
We are pleased to share that o2h Discovery has been recognised as the ‘Best Industry Support Partner of the Year’ at the OBN Awards 2025. This achievement reflects the dedication of our exceptional teams and the strong, collaborative partnerships we have built with various innovative biotech and pharma organisations worldwide. This award follows our 2023 ‘Most Impactful CRO Award’ and holds special significance for us. It also showcases the steady progress we’ve made in enabling partners to advance their discovery programmes, strengthened by long-standing relationships and shared…
Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions today announced the launch of an Integrated CMC Partnership designed to provide innovator biopharma companies with end-to-end Chemistry, Manufacturing and Controls (CMC) services. The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing.
Through this partnership, customers will have access to integrated drug substance and drug product development,…